OncoTherapy Science Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	808	750	610	1,134	1,153
Revenue Growth (YoY)	7.73%	22.95%	-46.21%	-1.65%	247.29%
Cost of Revenue	1,328	1,253	1,465	1,810	2,770
Gross Profit	-520	-503	-855	-676	-1,617
Selling, General & Admin	289	289	261	287	294
Other Operating Expenses	-	5	4	144	142
Operating Expenses	289	294	265	431	436
Operating Income	-809	-797	-1,120	-1,107	-2,053
Interest Expense	-1	-1	-	-	-
Currency Exchange Gain (Loss)	-2	1	-5	-8	-14
Other Non Operating Income (Expenses)	-33	-18	-12	-18	-5
EBT Excluding Unusual Items	-845	-815	-1,137	-1,133	-2,072
Gain (Loss) on Sale of Assets	-63	-	-	-	-
Asset Writedown	-	-	-154	-21	-547
Other Unusual Items	-	2	5	38	49
Pretax Income	-908	-813	-1,286	-1,116	-2,570
Income Tax Expense	2	2	2	2	1
Earnings From Continuing Operations	-910	-815	-1,288	-1,118	-2,571
Net Income	-910	-815	-1,288	-1,118	-2,571
Net Income to Common	-910	-815	-1,288	-1,118	-2,571
Shares Outstanding (Basic)	328	261	213	193	187
Shares Outstanding (Diluted)	328	261	213	193	187
Shares Change (YoY)	25.69%	22.73%	10.45%	2.76%	6.31%
EPS (Basic)	-2.77	-3.12	-6.05	-5.80	-13.71
EPS (Diluted)	-2.77	-3.12	-6.05	-5.80	-13.71
Free Cash Flow	-	-815	-1,229	-798	-2,529
Free Cash Flow Per Share	-	-3.12	-5.78	-4.14	-13.49
Gross Margin	-64.36%	-67.07%	-140.16%	-59.61%	-140.24%
Operating Margin	-100.12%	-106.27%	-183.61%	-97.62%	-178.06%
Profit Margin	-112.62%	-108.67%	-211.15%	-98.59%	-222.98%
Free Cash Flow Margin	-	-108.67%	-201.47%	-70.37%	-219.34%
EBITDA	-	-	-	-1,091	-2,037
EBITDA Margin	-	-	-	-96.21%	-176.67%
D&A For EBITDA	-	-	-	16	16
EBIT	-809	-797	-1,120	-1,107	-2,053
EBIT Margin	-100.12%	-106.27%	-183.61%	-97.62%	-178.06%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.